Substance Use Disorder Treatment Services and Coverage

Substance use disorder (SUD) treatment in the United States spans a layered system of clinical, regulatory, and insurance frameworks that determine what services are available, who qualifies, and how costs are shared. Federal law, including the Mental Health Parity and Addiction Equity Act (MHPAEA) and the Affordable Care Act (ACA), establishes minimum coverage standards across most insurance types. This page explains how SUD treatment is defined, how coverage mechanisms operate, what scenarios most commonly arise, and where classification boundaries affect access.

Definition and scope

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association, classifies substance use disorders as a spectrum of conditions involving impaired control, social impairment, risky use, and pharmacological criteria across 11 substance categories, including alcohol, opioids, stimulants, cannabis, and sedatives. Severity is graded as mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more criteria), and this classification directly influences which level of care is clinically recommended and which coverage tiers a payer may authorize.

Under the ACA (42 U.S.C. § 18022), substance use disorder services are designated as one of ten essential health benefits (EHBs), meaning all non-grandfathered individual and small-group market plans must include them. The scope of required SUD benefits includes screening, assessment, counseling, medication-assisted treatment (MAT), and residential services, though the specific benefit design — such as day limits or visit caps — must comply with parity requirements enforced by the Departments of Labor, Health and Human Services, and Treasury under MHPAEA (29 U.S.C. § 1185a).

The behavioral health parity law framework is central to understanding SUD coverage disputes, as parity violations most often surface in the form of stricter treatment limitations applied to SUD benefits compared to analogous medical or surgical benefits.

How it works

SUD treatment is organized into levels of care defined by the American Society of Addiction Medicine (ASAM) Patient Placement Criteria. Payers, including Medicaid managed care organizations and commercial insurers, frequently use ASAM criteria as the clinical standard for utilization review. The six primary ASAM levels are:

  1. Level 0.5 — Early intervention (screening and brief intervention)
  2. Level 1 — Outpatient services (fewer than 9 hours per week)
  3. Level 2.1 — Intensive outpatient program (IOP; 9–19 hours per week)
  4. Level 2.5 — Partial hospitalization program (PHP; 20 or more hours per week)
  5. Level 3 — Residential/inpatient treatment (sub-divided into 3.1 through 3.7 by medical management intensity)
  6. Level 4 — Medically managed intensive inpatient (hospital-based detoxification)

Coverage authorization typically follows a stepwise progression, though prior authorization requirements vary by plan and level. Medicaid is the single largest payer of SUD treatment services in the United States, covering 40 percent of adults receiving specialty SUD treatment (SAMHSA, National Survey of Substance Abuse Treatment Services, 2022).

Medication-assisted treatment (MAT) — which includes buprenorphine, methadone, and naltrexone — is regulated separately from general SUD counseling. Methadone for opioid use disorder (OUD) can be dispensed only through federally certified opioid treatment programs (OTPs) regulated under 42 CFR Part 8, administered by SAMHSA. Buprenorphine prescribing was historically restricted to waivered providers under the DATA 2000 Act. The Consolidated Appropriations Act, 2023 (enacted December 29, 2022) eliminated the X-waiver requirement effective upon enactment, expanding buprenorphine prescribing authority to any DEA-licensed practitioner with a Schedule III controlled substance registration. No separate waiver application or waiver-specific training is required. Practitioners must, however, comply with a one-time registration notification to DEA and adhere to updated DEA and SAMHSA practice guidelines issued following enactment.

Effective January 5, 2021, urban Indian organizations (UIOs) and their employees are deemed part of the Public Health Service for purposes of certain personal injury claims under federal law. This deeming status means that eligible UIO employees providing SUD treatment services receive federal tort claims protections equivalent to those afforded to Public Health Service personnel, affecting liability and claims frameworks for SUD services delivered through UIOs. Personal injury claims arising from covered services at UIOs are governed by the Federal Tort Claims Act framework applicable to Public Health Service entities, rather than standard private provider liability rules. This status applies to the organization and its employees collectively, covering both institutional and individual provider liability for covered services.

Common scenarios

Opioid use disorder with MAT: A patient diagnosed with severe OUD under DSM-5 criteria seeks buprenorphine. As of the Consolidated Appropriations Act, 2023 (enacted December 29, 2022), the X-waiver requirement has been eliminated; any DEA-licensed practitioner with a Schedule III registration may prescribe buprenorphine for OUD without obtaining a separate waiver or completing waiver-specific training. Practitioners must comply with a one-time DEA registration notification and adhere to updated DEA and SAMHSA practice guidelines. Insurers are required by parity standards not to impose prior authorization requirements on MAT that are more restrictive than those applied to comparable medical treatments. If the treating provider is out-of-network, in-network vs. out-of-network cost-sharing rules apply, which can substantially affect patient liability.

Residential treatment authorization denial: A patient assessed at ASAM Level 3.5 (clinically managed high-intensity residential) receives a payer denial citing medical necessity. Under MHPAEA, the plan must disclose the criteria used in the denial and demonstrate those criteria are no more stringent than those applied to analogous medical/surgical benefits. Filing a grievance through the healthcare complaint and grievance process is the procedural pathway for contesting such a denial.

Medicaid coverage for SUD services: Medicaid eligibility and enrollment determines whether SUD services are accessed through fee-for-service or managed care. The Substance Use Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (P.L. 115-271) required states to cover MAT for Medicaid beneficiaries with OUD beginning October 2020. States may also apply for Section 1115 waivers to cover residential SUD treatment services, which are otherwise excluded under the Institutions for Mental Diseases (IMD) exclusion at 42 CFR § 438.

Uninsured individuals: Federally Qualified Health Centers (FQHCs), listed under the Health Resources and Services Administration (HRSA) database, are required to provide SUD screening and referral regardless of ability to pay. Federally Qualified Health Centers operate on a sliding-fee-scale model established under Section 330 of the Public Health Service Act.

Urban Indian organizations: Effective January 5, 2021, urban Indian organizations and their employees are deemed part of the Public Health Service for purposes of certain personal injury claims under federal law. Individuals seeking SUD treatment through a UIO should be aware that liability and claims processes for personal injury arising from covered services follow the Federal Tort Claims Act framework applicable to Public Health Service entities, rather than standard private provider liability rules. This federal deeming status applies to the organization and its employees collectively, meaning both institutional and individual provider liability for covered services falls within the federal tort claims framework. Claims must be filed and adjudicated under the Federal Tort Claims Act procedures applicable to Public Health Service entities, rather than through standard private provider malpractice or personal injury channels.

Decision boundaries

Classification of a patient's situation into distinct coverage pathways depends on intersecting variables, not a single criterion. The primary decision boundaries are:

Insurance type: The EHB mandate applies only to individual and small-group non-grandfathered plans. Large employer self-insured plans are exempt from state EHB mandates but remain subject to MHPAEA. Medicare covers SUD treatment under Parts A (inpatient), B (outpatient counseling and MAT), and D (MAT medications); the Medicare-specific framework is detailed in the Medicare Parts A, B, C, D explained reference.

Diagnosis coding: ICD-10-CM codes in the F10–F19 range (Mental and behavioral disorders due to psychoactive substance use) drive billing and reimbursement classification. Incorrect specificity — such as coding a substance use disorder as abuse rather than dependence — can result in coverage mismatches. Medical billing and coding basics covers how coding specificity affects reimbursement eligibility.

Level-of-care vs. acute medical need: A patient requiring medically supervised withdrawal management (ASAM Level 4) is classified differently from one entering residential rehabilitation (Level 3.5). The former typically triggers inpatient acute care benefits; the latter may be processed under behavioral health or rehabilitation benefits with different cost-sharing structures under the member's explanation of benefits.

Parity compliance gap: Non-quantitative treatment limitations (NQTLs) — such as fail-first requirements, geographic limits on covered facilities, or formulary restrictions on MAT medications — are the most common mechanism through which SUD benefits fall out of parity. The Departments of Labor and HHS issued joint MHPAEA enforcement guidance in 2023 requiring plans to conduct comparative analyses of NQTLs and provide them upon request (DOL MHPAEA Enforcement Guidance, 2023).

Buprenorphine prescriber eligibility: The Consolidated Appropriations Act, 2023 (enacted December 29, 2022) eliminated the X-waiver requirement previously imposed under the DATA 2000 Act. Any DEA-licensed practitioner holding a Schedule III controlled substance registration may now prescribe buprenorphine for OUD without a separate waiver or waiver-specific training. Practitioners must comply with a one-time DEA registration notification and adhere to updated DEA and SAMHSA practice guidelines issued following enactment. This boundary is relevant when assessing whether a prescriber's credentials satisfy insurer credentialing requirements and whether coverage for buprenorphine prescriptions issued by newly eligible prescribers will be honored under a given plan's formulary and network rules.

Urban Indian organization provider status: Effective January 5, 2021, urban Indian organizations and their employees are deemed part of the Public Health Service for purposes of certain personal injury claims under federal law. This classification affects the legal framework governing liability for SUD services rendered at UIOs and is a relevant boundary when determining applicable claims processes for patients treated at these organizations. Personal injury claims arising from covered services at UIOs are governed by the Federal Tort Claims Act framework applicable to Public Health Service entities, rather than standard private provider liability rules. This deeming status applies to the organization and its employees collectively, meaning both institutional and individual provider liability for covered services falls within the federal tort claims framework. Claims must be filed under Federal Tort Claims Act procedures applicable to Public Health Service entities; standard private provider malpractice filing procedures do not apply.

Patient rights and responsibilities frameworks apply throughout SUD treatment, including rights to informed consent for MAT, confidentiality protections specific to SUD records under 42 CFR Part 2 (administered by SAMHSA), and access to medical records governed by HIPAA.

References

📜 9 regulatory citations referenced  ·  ✅ Citations verified Feb 25, 2026  ·  View update log

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Bmi Health Metrics Calculator